- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Clinical study of parathyroid hormone decreasing effect of cimetidine in chronic hemodialysis patients
-
- Date Toshiyuki
- Kidney Center, Mikasa Municipal General Hospital
-
- Chiba Eiichi
- Kidney Center, Mikasa Municipal General Hospital
-
- Sugawara Gotaro
- Jinyukai Takikawa Clinic
-
- Terada Masaiku
- Terada Clinic
-
- Enatsu Asamatsu
- Tomakomai Oji General Hospital
-
- Kumamoto Yoshiaki
- Department of Urology, Sapporo Medical College
Bibliographic Information
- Other Title
-
- 慢性血液透析症例におけるCimetidineによる副甲状線ホルモン分泌抑制効果の臨床的検討
Search this article
Description
Cimetidine, 400mg a day, was orally administered to the patients on chronic hemodialysis for a 4-week period and a 6-week period to determine mainly the reduction rates of serum parathyroid hormone (PTH).<br>1) Changes in PTH after the short-term cimetidine therapy.<br>In the group with markedly increased PTH (the pre-cimetidine therapy level of PTH being 8.03±3.63ng/ml), PTH dropped significantly to 5.67±2.94ng/ml within 4 weeks, but tended to increase after the cessation of cimetidine therapy. In the group with moderately increased PTH (the pre-cimetidine therapy level of PTH being 3.36±0.88ng/ml), PTH decreased moderately to 2.56±0.66ng/ml within 4 weeks. This decrement was not significant. In the both groups, serum calcium and phosphate did not show any significant change throughout the period of cimetidine therapy, suggesting that PTH reducing activity of cimetidine was not due the secondary effect of serum calcium.<br>2) Changes in PTH after the long-term cimetidine therapy.<br>The PTH levels in 5 patients belonging to the group with markedly increased PTH were 7.66±3.91ng/ml before the cimetidine therapy, but dropped significantly to 5.17±3.05ng/ml in one month and to 3.63±1.12ng/ml 6 months after the cimetidine treatment. In the patient with abnormally high PTH level (14.39ng/ml), even a minimal dose of 1-alpha-(OH)-D3 induced hypercalcemia promptly, thus a sufficient amount of 1-alpha-(OH)-D3 could not be given, and the patient complained of severe bone pain. However, as the PTH level decreased with cimetidine therapy, an increased dose of 1-alpha-(OH)-D3 did not produce hypercalcemia, and bone pain disappeared.<br>3) Changes in the serum cimetidine concentration and it's reduction rates during and after hemodialysis.<br>After the oral administration of cimetidine 200mg, the serum cimetidine concentration reached a maximal level of 1.84±0.63μg/ml in 4 hours and decreased gradually thereafter to 0.86±0.33μg/ml by 10 hours. Even after the continuous administration for 4 weeks, there were no signs of the accumulation.<br>The reduction rate of serum cimetidine concentration per single hemodialysis was 69.2±10.5% after 5 hours of hemodialysis using a dialyzer with a mean membrane surface area of 1.3M2.<br>Cimetidine therapy to the patients with uncontrollable secondary hyperparathyroidsm in considered worthwhile to attempt before performing subtotal prathyroidectomy.
Journal
-
- Journal of Japanese Society for Dialysis Therapy
-
Journal of Japanese Society for Dialysis Therapy 15 (3), 325-334, 1982
The Japanese Society for Dialysis Therapy
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282680319896576
-
- NII Article ID
- 130003707370
-
- ISSN
- 18846203
- 02887045
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed